Mironid raises $46M Series B

Mironid, a Glasgow-based biopharmaceutical company developing small molecule therapeutics for Autosomal Dominant Polycystic Kidney Disease (ADPKD), announced on August 5, 2026 that it raised $46 million in a Series B funding round. The round was led by new investor Scotland — Scottish National Investment Bank, with participation from existing investors Roche Venture Fund, Epidarex Capital, Sofinnova Partners, BioGeneration Ventures, and the University of Strathclyde. Proceeds will fund clinical development of Mironid's first-in-class LoAc small molecule candidate, which targets cyclic AMP (cAMP) to potentially treat ADPKD, a hereditary kidney disorder affecting over 12 million people worldwide. The company, spun out of the University of Strathclyde and Heriot-Watt University in 2015, has completed IND-enabling studies and aims to generate initial clinical data with the new capital. The funding follows a Series A extension in 2023, bringing total funding to approximately €40.8 million.